Free Trial
NASDAQ:ZVSA

ZyVersa Therapeutics Q1 2025 Earnings Report

ZyVersa Therapeutics logo
$0.14 -0.01 (-4.79%)
As of 02:52 PM Eastern

ZyVersa Therapeutics EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.40
Beat/Miss
Missed by -$0.33
One Year Ago EPS
N/A

ZyVersa Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ZyVersa Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
9:30AM ET

Earnings Documents

ZyVersa Therapeutics Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More ZyVersa Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ZyVersa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ZyVersa Therapeutics and other key companies, straight to your email.

About ZyVersa Therapeutics

ZyVersa Therapeutics (NASDAQ:ZVSA), a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

View ZyVersa Therapeutics Profile

More Earnings Resources from MarketBeat